On March 27, 2026, the Company entered into a securities purchase agreement (the “2026 PIPE Purchase Agreement”) with certain institutional accredited investors (the “2026 PIPE Investors”), pursuant …
In connection with the Merger Agreement, certain parties entered into a subscription agreement with the Company to purchase shares of Reneo’s common stock for an aggregate purchase price of $ 65.0 million
In connection with the Merger Agreement, certain parties entered into a subscription agreement with the Company to purchase shares of Reneo’s common stock for an aggregate purchase price of $ 65.0 million
uction of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. Furthermore, we rely on single-source suppliers for our drug substance …
OnKure Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
OKUR-DEBT
Debt stack $409,000
90%
Market cache reports total debt of $409,000.
OKUR-DEBT-11502
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
OnKure Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for OnKure Therapeutics, Inc..
OnKure Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
OKUR-OWNER-RA-CAPITAL-MANAGEMENT-L-P
RA CAPITAL MANAGEMENT, L.P.
90%
13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 51 tracked holders.
OnKure Therapeutics, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
